S118: LONG-TERM SAFETY AND EFFICACY OF VOXELOTOR FOR PATIENTS WITH SICKLE CELL DISEASE: RESULTS FROM AN OPEN-LABEL EXTENSION OF THE PHASE 3 HOPE TRIAL

• M Achebe,
• V Nduba,
• H Hassab,
• S Alkindi,
• R Brown,
• P Telfer,
• B Biemond,
• V Gordeuk,
• T Lipato,
• M Tonda,
• S Gray,
• J Howard

Affiliations

M Achebe

1 Brigham and Women’s Hospital, Harvard Medical School, Boston, Boston, UNITED STATES

V Nduba

2 Kenya Medical Research Institute, Kisumu, KENYA

H Hassab

3 Pediatric Department & Clinical research center, Faculty of Medicine, Alexandria University, Alexandria, EGYPT

S Alkindi

4 Sultan Qaboos University, Muscat, OMAN

R Brown

5 Aflac Cancer and Blood Disorders Center of Children’s Healthcare of Atlanta and Department of Pediatrics, Emory University, Altanta, UNITED STATES

P Telfer

6 Queen Mary, University of London, London, UNITED KINGDOM

B Biemond

7 Academic Medical Centre, University of Amsterdam, Amsterdam, NETHERLANDS

V Gordeuk

8 University of Illinois Hospital, Chicago, UNITED STATES

T Lipato

9 Virginia Commonwealth University Medical Center, Richmond, UNITED STATES

M Tonda

10 Global Blood Therapeutics, South San Francisco, UNITED STATES

S Gray

10 Global Blood Therapeutics, South San Francisco, UNITED STATES

J Howard

11 Guy’s and St. Thomas’ NHS Foundation Trust, King’s College, London, UNITED KINGDOM